Wells Fargo analyst David Maris maintained an Outperform rating on Jazz Pharmaceuticals and raised his price target to $182 from $176 on Jazz shares. The analyst also raised his 2018 EPS estimate to $13.00 from $12.91 after Jazz's beat and raise quarter, and raised his outer year Xyrem growth forecasts from 8% to 10% in 2019, from 6% to 8% in 2020 and from 4% to 5% in 2021, based on Xyrem's return to stronger growth in Q1. Maris concluded that he liked " the conservative balance sheet and potential for strategic deals, the current sales trends, and the focus on pipeline progress."